Is an MBA the right decision for me?

Article

Taking the first step towards analysing your career goals and the return on your investment.

Key Points

Whatever the reason, increasing numbers of ophthalmologists are taking the plunge and getting their MBAs. We hope this will help provide guidance through the process.

The decision about whether pursuing an MBA will be worthwhile hinges on what you are doing now and how you envision your ideal future. For example, doctors who specialize in laser vision correction or oculoplastic surgery might realize that because a significant portion of their businesses involve nonmedical decision-making, including how to market their practices, it would make good sense to learn more about the business side by obtaining an MBA.

Many physicians argue that having an MBA is becoming increasingly necessary with the changes in medicine. Eric Seaman, MD, a urologist, wrote in October 2004 in the Journal of the National Medical Association that he pursued an MBA because he believed that doctors were (and are) losing control of the ability to shape their destinies.

"Market forces, government initiatives, and certain lobbies continue to place more and more burden onto the shoulders of physicians," he wrote. One solution, according to Dr. Seaman, is for doctors to enhance their business knowledge.

My colleagues in academic medicine are pursuing an MBA in search of career advancement because many universities and other institutions are demanding that upper-level administrators not only have the academic credentials and clinical skills but also a business background (for example, an understanding of how to control costs, increase revenue).

Dr Kelly Hutcheson, associate professor of ophthalmology and pediatrics, Children's National Medical Centre and George Washington University School of Medicine, Washington, DC, decided after a decade in academic medicine that her goal was to become more involved in the administration of the hospital and her department. To increase her professional worth, Dr Hutcheson is obtaining her MBA at George Washington University part-time. As part of the faculty, she receives a discount of up to 50% on her courses.

Yet another category of doctors who would be motivated to obtain an MBA are those who are considering a transition to investment banking (Wall Street), hedge funds, the pharmaceutical industry, or consulting. For example, when I was obtaining my MBA at New York University's (NYU) Leonard N. Stern School of Business as a part-time student from 2000 to 2004, I was considering transitioning to a management consulting firm. This new career offered better hours, a more attractive lifestyle, and higher income potential. To investigate this possibility further, I decided to go through the formal career placement track at NYU and interviewed with top management-consulting firms. I made it to the final round before I withdrew myself because I decided to remain in clinical medicine. The process was extremely useful, however, in providing a more complete picture of what my options outside of clinical medicine could be later in life as a second career.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.